Hapvida Participacoes e Investimentos (HAPV3) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Management is executing a strategic transformation plan focused on margin recovery, cash generation, deleveraging, and improving the user journey, with compensation tied to these metrics.
Initiatives include commercial transformation, network optimization, administrative efficiency, legal restructuring, and investments in digital channels and process redesign.
Net revenue grew 3.9% year-over-year and 1.0% sequentially, driven by higher average ticket size and price adjustments.
Significant expansion activities included the acquisition of Grupo Cubo Mágico and the incorporation of São Lucas Saúde and related entities.
Early signs of improvement in strategic portfolios and contract renegotiations, with a focus on profitability and stricter renewal criteria.
Financial highlights
Net revenue reached R$7,974 million in 2Q26, up 3.9% year-over-year and 1.0% sequentially; 1H26 net revenue was R$15.87 billion.
Adjusted EBITDA for 2Q26 was R$504.4 million (6.3% margin), down 44.3% year-over-year and 37.2% sequentially.
Adjusted net income for 2Q26 was R$12.5 million, a sharp decline from R$299.5 million in 2Q25.
Net debt increased to R$5,401 million as of June 2026, with leverage at 1.61x EBITDA LTM.
Cash medical loss ratio (MLR) rose to 75.2% in 2Q26, up 303bps sequentially.
Outlook and guidance
Management expects transformation initiatives and restructuring to yield results over the next quarters, with full impact anticipated by 2027.
Focus on repricing or terminating loss-making contracts, optimizing network, and digitalizing administrative processes to drive margin recovery and cash generation.
CapEx guidance for 2026 is about R$700 million, after R$363 million spent in the first half.
ANS fines are expected to stabilize for two more quarters before decreasing.
Management affirms sufficient resources and no material uncertainties regarding going concern for the next 12 months.
Latest events from Hapvida Participacoes e Investimentos
- Net revenue rose 5.2% YoY to R$7.9B, with EBITDA at R$803M and improved cash MLR.HAPV3
Q1 2026 - Clear operational focus, strong governance, and disciplined growth drive long-term value creation.HAPV3
Investor presentation - Net revenue up 5.9% YoY, but margin and beneficiary base declined amid cost and competitive pressures.HAPV3
Q4 2025 - Net revenue up 6.0% YoY, adjusted EBITDA at R$746.4M, and cash MLR at 75.2%.HAPV3
Q3 2025 - Net revenue rose 7.3% to R$7.67B, with strong beneficiary growth and resilient margins.HAPV3
Q2 2025 - Revenue and margins improved, with net debt at 0.97x EBITDA and strong cash flow.HAPV3
Q3 2024 - Adjusted EBITDA up 58% year-over-year, margin at 13.4%, net debt/EBITDA at 1.03x.HAPV3
Q2 2024 - Strong revenue and margin growth, improved cash flow, and reduced liabilities in 2024.HAPV3
Q4 2024 - Revenue up 7.3% YoY, leverage down to 0.98x, but adjusted net income declined on legal costs.HAPV3
Q1 2025